Protective effect of policosanol on endothelium and intimal thickness induced by forceps in rabbits

Journal of Medicinal Food

Volumn 10, Issue 3, 2007, Pages 452-459

  Noa, Miríam ^a   Más, Rosa ^a   Lariot, Carlos ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Endothelium; Intimal thickness; Policosanol; Rabbit

Indexed keywords

ACETYLSALICYLIC ACID; POLICOSANOL; POLYSORBATE 20; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTERY INJURY; ARTERY INTIMA; ARTERY WALL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; EAR; ENDOTHELIUM INJURY; FORCEPS; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SCANNING ELECTRON MICROSCOPY; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIES; ATHEROSCLEROSIS; BLOOD PLATELETS; EAR; ENDOTHELIUM, VASCULAR; FATTY ALCOHOLS; MALE; MICROSCOPY, ELECTRON; MICROSCOPY, ELECTRON, SCANNING; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; RABBITS; SURGICAL INSTRUMENTS; TUNICA INTIMA;

ANIMALIA; ORYCTOLAGUS CUNICULUS; RATTUS; SACCHARUM;

EID: 34848911663     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2006.232     Document Type: Article

References (52)

1. Mas R: Policosanol. Drugs Future 2000;25:569-586.
2. Ortensi G, Gladstein H, Valli H, Tesone PA: A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res 1997;58:390-401.
3. Mas R, Castaño G, Illnait J, et al.: Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999;65:439-447.
4. Castaño G, Más R, Fernández L, et al.: Effect of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000;13:187-195.
5. Castaño G, Más R, Fernández JC, et al.: Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A 2001;56:M186-M192.
6. Mas R, Castaño G, Fernández L, et al.: Effects of policosanol in older hypercholesterolemic patients with coronary disease. Clin Drug Invest 2001;21:485-497.
7. Torres O, Agramonte A J, Illnait J, et al.: Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995;18:393-397.
8. Castaño G, Menéndez R, Más R, et al.: Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated to type 2 diabetes mellitus. Int J Clin Pharmacol Res 2002;22:89-99.
9. Castaño G, Fernández L, Mas R, et al.: Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation on patients with dyslipidemia and Type 2 diabetes mellitus. Drugs Aging 2003;20:155-163.
10. Menéndez R, Fernández SI, Del Rio A, et al.: Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblast. Biol Res 1994;27:199-203.
11. Menéndez R, Arruzazabala ML, Más R, et al.: Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Br J Nutr 1997;77:923-932.
12. Menéndez R, Amor A, Rodeiro I, et al.: Policosanol modulates HMGCoA reductase activity in cultured fibroblasts. Arch Med Res 2001;32:8-12.
13. Singh D, Li L, Porter T: Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther 2006;318:1020-1026.
14. Noa M, Magraner J, Más R: Efecto del Ateromixol en las lesiones aorticas inducidas por lipofundin en conejos. Prog Cien Med (Venezuela) 1992;6:14-19.
15. Noa M, Más R, de la Rosa MC, Magraner J: Effect of policosanol on lipofundin-induced lesions in rats. J Pharm Pharmacol 1995;47:289-291.
16. Noa M, M-s R, de la Rosa MC: Effect of policosanol on foam cell formation in carrageenan-induced granulomas in rats. J Pharm Pharmacol 1996;48:306-309.
17. Rodriguez C, Mesa R, Más R, Noa M, Menendez R, Gonzalez R: Effects of policosanol chronically administered in male monkeys (Macaca arctoides). Fund Chem Toxicol 1994;32:565-575.
18. Noa M, Más R: Protective effect of policosanol on atherosclerotic plaque on aortas in monkeys. Arch Med Res 2005;36:441-447.
19. Noa M, Más R, Mesa R: Effect of policosanol on intimal thickening in rabbit cuffed carotid artery. Int J Cardiol 1998;67:125-132.
20. Noa M, Más R, Mesa R: A comparative study of policosanol versus lovastatin on intimal thickening in rabbit cuffed carotid artery. Pharmacol Res 2001;43:31-37.
21. Arruzazabala ML, Carbajal D, Más R, García M, Fraga V: Effects of Ateromixol on platelet aggregation in rats. Thromb Res 1993;69:321-327.
22. Arruzazabala ML, Molina V, Carbajal D, Valdés S, Más R: Effect of policosanol on cerebral ischemia in Mongolian gerbils: role of prostacyclin and thromboxane A2. Prostaglandins Leukot Essent Fatty Acids 1993;49:695-699.
23. Noa M, Más R, Briñis F, Mesa R: Effect of policosanol on circulating endothelial cells in experimental models. J Pharm Pharmacol 1997;49:999-1003.
24. Schwartz CJ, Kelley JL, Nerem RM, Sprague EA, Rosck M, Valente A: Pathophysiology of the atherogenic process. Am J Cardiol 1989;64:236-306.
25. Ip J, Fuster V, Badimón L, Badimón J, Taubman M, Chesebro J: Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990;15:1667-1687.
26. Guyton JR, Moake JL: Thrombotic processes in atherogenesis. In: Blood Vessel Wall and Thrombosis, Vol. II (Machovich R, ed.), CRC Press, Boca Raton, FL, 1988, pp. 1-23.
27. Fanelli C, Aronoff R: Restenosis following coronary angioplasty. Am Heart J 1990;119:357-368.
28. Silver MJ, Ingerman-Wojenski CM, Sedar AW, Smith M: Model system to study interaction of platelets with damaged arterial wall. I. Inhibition of platelet adhesion to subendothelium by aspirin and dipyridamole. Exp Mol Pathol 1984;41:141-152.
29. Ingerman-Wojenski CM, Silver MJ: Model system to study interaction of platelets with damaged arterial wall. II. Inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719. Exp Mol Pathol 1988;48:116-134.
30. th International Symposium of Atherosclerosis (Schetler FB, ed.), Springer-Verlag, New York, 1983, pp. 25-28.
31. rd ed. (Antonaccio M, ed.), Raven Press, New York, 1990, pp. 18-24.
32. Hladovec J: Antithrombotic Drugs in Thrombosis Models, CRC Press, Boca Raton, FL, 1989.
33. Atkinson D, Hoover R, Berry K, Swilt L: Cholesterol-fed heterozygous Watanabe heritable hyperlipidemic rabbits: a new model for atherosclerosis. Atherosclerosis 1989;79:123-136.
34. 2-induced vascular endothelial cell damage and respiratory smooth muscle cell contraction: inhibition by flunarizine, a Ca-overload blocker. Arch Int Pharmacodyn Ther 1985;274:4-23.
35. Zaman A, Helft G, Worthley S, Badimón J: The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 2000;49:251-266.
36. Arruzazabala ML, Carbajal D, GarcÌa M: Levamisol: un inhibidor de la enzima tromboxano sintetasa. Rev Latinoam Tromb Hemost 1990;111:19-21.
37. 2. Rev CENIC Cien Biol 1990;21:2-3.
38. Roth G, Calverley D: Aspirin, platelets and thrombosis: theory and practice. Blood 1994;83:885-898.
39. Hladovec J, De Clerck F: Protection by flunarizine against endothelial cell injury in vivo. Angiology 1981;32:448-462.
40. Valdés S, Arruzazabala ML, Fernández L, et al.: Effect of policosanol on platelet aggregation in healthy volunteers. Int J Clin Pharm Res 1996;XVI:67-72.
41. Carbajal D, Arruzazabala ML, ValdÈs S, M-s R: Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostaglandins Leukot Essent Fatty Acids 1998;58:61-64.
42. Soma M, Corsini A, Paoletti R: Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicol Lett 1992;64-65:1-15.
43. th International Symposium on Drugs Affecting Lipid Metabolism, Baylor University, Houston, 1995.
44. Pomerantz KB, Hajjar DP: Eicosanoids in regulation of arterial smooth muscle cell phenotype, proliferative, capacity and cholesterol metabolism. Arteriosclerosis 1989;9:413-429.
45. Menéndez R, Fraga V, Amor AM, González RM, Más R: Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation. Physiol Behav 1999;67:1-7.
46. Menendez R, Mas R, Amor AM, et al.: Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000;50:255-262.
47. Matrisian LM: The matrix degrading metalloproteinases. Bioessays 1992;14:455-463.
48. Bennett M, Evan G, Schwartz S: Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995;95:2266-2274.
49. Angelini A, Visona A, Pettenazzo E, Calabrese F, Yacoub A: Proliferation and cellular death (apoptosis) in an animal model of accelerated atherosclerosis. Atherosclerosis 1997;134:267-276.
50. Bär PR: Apoptosis - the cell's silent exit. Life Sci 1996;59:369-378.
51. Ghavami S, Barczyck K, Maddika S, et al.: Monitoring of programmed cell death in vivo and in vitro - new and old methods of cancer therapy assessment. In: Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases (Los M, Gibson SB, eds.), Springer, New York, 2005, pp. 323-341.
52. Hardwick SJ, Hegyi L, Clare K: Apoptosis in human monocyte-macrophages exposed to oxidized low density lipoprotein. J Pathol 1996;179:294-302.